Quantum Leap Energy LLC, a subsidiary of ASP Isotopes Inc. (NASDAQ: ASPI), entered into a non-binding memorandum of understanding with an unidentified European nuclear technology company for potential collaboration on high assay low enriched uranium supply.

Under the MOU terms, the parties will conduct technical and economic assessments to determine viability of long-term collaboration for HALEU supply with uranium-235 content exceeding 10%. The framework envisions the European partner providing uranium feedstocks to Quantum Leap Energy's planned conversion and enrichment facilities, with Quantum Leap Energy enriching the feedstocks to produce HALEU for delivery to the partner company.

The MOU extends through December 31, 2030, with potential for early termination by either party. Activities include assessment of operational requirements, production scalability for conversion and enrichment, and associated costs and commercial models. The agreement includes non-binding estimates for HALEU quantities with potential deliveries beginning in 2028 and scaling through 2036.

"Securing reliable HALEU supply is one of the most critical challenges facing the advanced nuclear industry today," said Dr. Ryno Pretorius, Chief Executive Officer of Quantum Leap Energy.

Quantum Leap Energy focuses on uranium conversion, enrichment of uranium-235 for nuclear fuel production, and isotopic separation technologies. The company holds exclusive global rights to proprietary Aerodynamic Separation Process and Quantum Enrichment technologies. ASP Isotopes operates isotope enrichment facilities in Pretoria, South Africa.

The information is based on a company press release.